Pharmaceutical Pricing and Contracting: An Overview March 2006

Slides:



Advertisements
Similar presentations
Issues and Compliance Strategies Related to Government Pricing Joseph W. Metro.
Advertisements

Beyond Average Wholesale Price….
Understanding Mail Order Community pharmacists provide a valuable service desired by patients. Very rarely are mail order and community pharmacies allowed.
Average Wholesale Price (AWP) Sapna N. Patel UCSF Pharm. D. Candidate 2008 Preceptor Dr. Craig S. Stern March 7, 2008.
Overview of Drug Purchasing & Pricing
Pharmacy Benefit Managers (PBMs)
Federal Upper Limit Dimitry Gotlinsky Western University.
INTEGRITY ● ACCESS ● VALUE 1 The 340B Drug Pricing Program: The Basics Paul Shank Health & Human Services Consultant, Health Resources and Services Administration.
Covering Analyst: Cecilia Xia
Workers Compensation Medical Fee Schedule Overview Paul Smallcomb Client Service Manager Medical Group Business Services.
State Maximum Allowable Cost (SMAC) Implementation Updates and Changes to DC Point-of-Sale Pricing Structure.
Are Drug Pricing Formulas Full Employment Acts For State Attorney Generals? Gerard Anderson PhD Professor Johns Hopkins University.
PBM Transactions Medicaid DRA Rule –Proposed Rule AMP includes “Discounts, rebates or other price concessions to PBMs associated with sales for drugs provided.
# Operating Under the New Compliance Environment: Considerations for the Pharmaceutical Industry The Impact of the new Medicare Prescription Drug benefit.
340B: An Overview.
Recent Pricing and Coverage Issues and Their Fraud and Abuse Implications Bill Sarraille
Government Price Reporting Obligations “A Compliance Discussion”
Medicare Modernization Act: Impact of State Implementation Decisions Haiden Huskamp AcademyHealth June 28, 2005.
Special Issues in M&A Transactions for Marketed Products John A. Hurvitz Covington & Burling Washington, DC (202)
Avalere Health LLC | The intersection of business strategy and public policy Medicaid Pharmacy Reimbursement Overview June 13, 2007 Jennifer Kowalski Avalere.
State Opportunities under the 340B Drug Discount Program by Bill von Oehsen Counsel Public Hospital Pharmacy Coalition Phone:
National Pharma Audioconference: Pharmaceutical Drug Pricing and Reporting Issues July 28, 2005 Government Price Reporting: Common Problem Areas in a Complex.
Focus on the Drug Payment Methods Landscape Academy of Managed Care Pharmacy April 17, 2009.
National Health Expenditures as a Share of Gross Domestic Product (GDP) FIGURE 7.1 Between 2001 and 2011, health spending is projected to grow 2.5 percent.
Slide 1 Drug Pricing Considerations Medicare Prescription Drug, Improvement, and Modernization Act of 2003 ___________ Copyright 2005 Arnold & Porter July.
PwC Pharmaceutical Drug Pricing and Reporting Issues A Brief Overview of Government Drug Price Reporting Requirements July 28, 2005 National Parma Audioconference.
© Hogan & Hartson LLP. All rights reserved. Alice Valder Curran, Partner Tuesday, October 17, 2006 Private Prices, Public Markets: The Evolution of Price.
1 Medicare Prescription Drug, Improvement, and Modernization Act of 2003 Title III – Combating Waste, Fraud, and Abuse Janet Rehnquist, Esq. Venable LLP.
GOVERNMENT CONTRACTS: FALSE CLAIMS AND COMPLIANCE Robert M. Jenkins III Mayer, Brown & Platt Presentation To The Fifth Annual National Congress on Health.
 Putting Numbers on the New Medicare Prescription Drug Legislation: How the MMI Will Affect Medicare Beneficiaries and Pharmaceutical Revenues Jack.
Avalere Health LLC | The intersection of business strategy and public policy Overview of Coverage of Drugs Under the Medicaid Medical Benefit June 4, 2008.
Timothy J. Nugent PricewaterhouseCoopers LLP November 7, 2005
FY 2008 Medicaid Budget Update Medicaid Advisory Committee Meeting April 26, 2007.
©2004 Deloitte Development LLC. All rights reserved. Medicare Drug Price Reporting and Reimbursement David Rogers Partner, Health Care Regulatory, Deloitte.
Enforcement Trends in the Pharmaceutical Industry Lewis Morris Chief Counsel Office of Inspector General, DHHS.
Managed Care Pharmacy Financials January 15, 2015.
How Pharmacy Benefit Managers Work April 28, 2016 Producer: Alexander Perry Director: Afzal Bari.
Pharmacy Benefit Management (PBM) 101
Office of Pharmacy Affairs 340B Drug Pricing Program Bradford R. Lang JD, MPH Public Health Analyst US Dept. of Health and Human Services Health Resources.
Drug Payment Methodologies
340B PROGRAM AND BEST PRICE LAW HIGPA 2003 National Pharmacy Forum February 4, 2003 Presentation By Ted Slafsky Director Public Hospital Pharmacy Coalition.
Reimbursement Trends & Observations Presented by: John Aforismo B.Sc. Pharm., R.Ph Chairman & Founder RJ Health Systems International, LLC AMCP 21 st Annual.
Connecticut Pharmaceutical Forum: Access, Affordability, and Better Health Tara C. F. Ryan May 17, 2016.
Drug Payment Methodologies Presentation Developed for the Academy of Managed Care Pharmacy Updated: February 2016.
Medicaid Influence in the Drug Market Dana Costea PhD student, Department of Economics, Lehigh University Franklin Carter Assistant Professor, Marketing.
MEDICATION USE IN RURAL AMERICA ASSOCIATION UPDATES National Community Pharmacists Association Tina Schlecht, PharmD, MBA Director, Pharmacy Affairs.
Analyzing the Impact of the DRA on the 340B Program by Stuart Yael Gordon Director of Legal and Regulatory Affairs Safety Net Hospitals for Pharmaceutical.
Changes to AMP & Best Price: Impact on 340B Pricing February 1, 2008 Long Beach, California 4 th Annual 340B Coalition Winter Conference University of.
Hemophilia Alliance Fall Meeting 2017
What are Pharmacy Benefit Managers?
Lauren Geyer Barnes Avalere Health LLC
Christopher C. Biddle, Vice President of Life Sciences Strategy
A Short History of Pricing Related Fraud and Abuse Issues 8th Annual Pharmaceutical Regulatory Compliance Congress and Best Practices Forum Washington,
340B: Overview of the Program and Legislative Update
Medicare Prescription Drug, Improvement, and Modernization Act of 2003 Title III – Combating Waste, Fraud, and Abuse Janet Rehnquist, Esq. Venable.
John M. Coster, Ph.D., R.Ph. Vice President, Policy and Programs
Pharmacy: Pharmacy Landscape and Uncovering the Optical Illusions
Brussels, June 6, 2007 Paul E. Kalb, M.D., J.D.
Andrew Ruskin Vinson & Elkins LLP Washington, DC
Medicare Part D Benefit: A Primer
“Netting” Prices Pharmaceutical Compliance Congress November 15, 2004
Part B Reimbursement for 2004
Medicare Rx Legislation: Implications for PBMs
Drug Payment Methodologies
Pharmacy Reimbursement and Manufacturer Rebate Formulas (Part 3)
Medicaid Drug Reimbursement Methodology
By Robert G. Homchick Davis Wright Tremaine LLP
Pharmacy Benefit Manager
Together, We Care More Meet MMCAP Infuse.
Drug Payment Methodologies
Presentation transcript:

Pharmaceutical Pricing and Contracting: An Overview March 2006 Lauren Barnes

Pharmaceutical Pricing Definitions (illustration based on fictional $100 product) AWP (Average Wholesale Price) $125 Spread of 25% on top of WAP 95% AWP (Medicare Reimbursement) $118.75 WAP or WAC (List or Wholesaler Acquisition Price) $100 Spread of Average Discounts 10% taken from WAP AMP (Average Manufacturer’s Price to Retail) $ 98 ASP (Average Sales Price) $ 90 Best Price (Most Favored Customer Price with <15.1% off AMP) $ 85 Medicaid Submission Price (15.1% off AMP) $ 83.20 FSS Price (Federal Supply Schedule 76% of Non-FAMP less CPI-U fees + 0.5% IFF – Industrial Funding Fee) $ 74.49

There are Various Entities Who Can Receive Discounts from Manufacturers Wholesaler Prompt Pay Discounts Purchaser Discounts Back end rebates Ships Product Payer Rebates Pharmacy Hospital Physician Office Government

A Variety of Discounts are Offered to Customers $100 product Prompt Pay Discount: 2% Physician Office Off Invoice Discount: 10% Manufacturer Wholesaler Pays $100 to manufacturer $ 2 prompt pay discount $10 rebate to wholesaler Pays $90 to wholesaler Physician Office 10% Back-end rebate based upon: Clinical metrics Volume threshold Market share goal $9 rebate to physician office

Medicaid Receives Payment from Manufacturer and the Federal Government $125 AWP/$100 WAC/ AMP = $90 CMS National Manufacturer Manufacturer Medicaid Matching Funds Disseminated CMS Sets Federal Upper Limits for Drugs Medicaid Rebate = $13.5 Pharmacy Medicaid Pharmacy Reimbursement = 90% AWP = $112.50 Dispensing Fee = $4.00

AMP Reform is Critical to Future Manufacturer Rebates as well as Medicaid Reimbursement The DRA mandated that the definition of AMP be clarified There are a number of outstanding issues in regard to calculating AMP: Determining if certain rebates are included in AMP Long term care pharmacy PBM Clarifying how prompt pay terms and fair-market-value fees are incorporated Addressing lagged price concessions, returned goods, and update frequency AMP reform will have two primary impacts on the industry: Medicaid rebate calculations and payments Medicaid pharmacy reimbursement rates